309 related articles for article (PubMed ID: 2823722)
21. [Clinical evaluation of serum NSE and CEA in primary lung cancer patients].
Fukasawa T; Fujisawa T; Yamaguchi Y; Sasaki K; Shiba M; Yusa T; Sakio H; Momiki S; Ogawa T
Gan To Kagaku Ryoho; 1986 May; 13(5):1862-7. PubMed ID: 3010884
[TBL] [Abstract][Full Text] [Related]
22. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of the degree of regression of small cell lung neoplasm in clinical-radiologic evaluation with levels of neuron specific enolase (NSE) in serum].
Rowińska-Zakrzewska E; Szturmowicz M; Sakowicz A; Pawlicka L; Remiszewki P; Szopiński J; Wiatr E; Zych J
Pneumonol Alergol Pol; 1995; 63(11-12):601-8. PubMed ID: 8616474
[TBL] [Abstract][Full Text] [Related]
24. [The prognostic value of serum neuron specific enolase detection in small cell lung cancer].
Jin B; Zhao L; Zhou C
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Dec; 24(12):722-4. PubMed ID: 11930699
[TBL] [Abstract][Full Text] [Related]
25. Elevated serum creatine kinase BB levels in patients with small cell lung cancer.
Carney DN; Zweig MH; Ihde DC; Cohen MH; Makuch RW; Gazdar AF
Cancer Res; 1984 Nov; 44(11):5399-403. PubMed ID: 6091876
[TBL] [Abstract][Full Text] [Related]
26. Neuron-specific enolase in small-cell carcinoma of the lung: the value of combined immunocytochemistry and serum determination.
Esscher T; Bergh J; Steinholtz L; Nöu E; Nilsson K; Påhlman S
Anticancer Res; 1989; 9(6):1717-20. PubMed ID: 2560624
[TBL] [Abstract][Full Text] [Related]
27. High neuron specific enolase levels in bronchoalveolar lavage fluid of patients with lung carcinoma: diagnostic value, relation to serum neuron specific enolase, and staging.
Dowlati A; Bury T; Corhay JL; Weber T; Mendes P; Radermecker M
Cancer; 1996 May; 77(10):2039-43. PubMed ID: 8640667
[TBL] [Abstract][Full Text] [Related]
28. [Neuron-specific enolase as a tumor marker in small cell bronchial carcinoma].
Gasser RW; Herold M; Müller-Holzner E; Müller LC; Salzer GM; Huber H
Dtsch Med Wochenschr; 1988 Nov; 113(44):1708-13. PubMed ID: 2846253
[TBL] [Abstract][Full Text] [Related]
29. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
Yang J; Li R; Li A
Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of serum neuron-specific enolase as a tumor marker for carcinoma of the lung.
Ariyoshi Y; Kato K; Ishiguro Y; Ota K; Sato T; Suchi T
Gan; 1983 Apr; 74(2):219-25. PubMed ID: 6305752
[TBL] [Abstract][Full Text] [Related]
32. Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer.
Tiseo M; Ardizzoni A; Cafferata MA; Loprevite M; Chiaramondia M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Anticancer Res; 2008; 28(1B):507-13. PubMed ID: 18383893
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
[TBL] [Abstract][Full Text] [Related]
34. [Evaluation of tumor markers in the management of small cell lung cancer].
Ariyoshi Y
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
36. Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer.
Akoun GM; Scarna HM; Milleron BJ; Bénichou MP; Herman DP
Chest; 1985 Jan; 87(1):39-43. PubMed ID: 2981171
[TBL] [Abstract][Full Text] [Related]
37. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
38. Cut-off levels of NSE to differentiate SCLC from NSCLC.
Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K
Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic value of neuron enolase levels in serum of patients with lung neoplasms].
Jassem E; Gan J; Cynowska B
Pneumonol Alergol Pol; 1995; 63(7-8):415-20. PubMed ID: 8520560
[TBL] [Abstract][Full Text] [Related]
40. Methodological and clinical evaluation of two automated enzymatic immunoassays as compared with a radioimmunoassay for neuron-specific enolase.
Schmitt UM; Stieber P; Hasholzner U; Pahl H; Hofmann K; Fateh-Moghadam A
Eur J Clin Chem Clin Biochem; 1996 Aug; 34(8):679-82. PubMed ID: 8877347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
